Patients with diabetes are increasingly exploring fasting for religious, cultural, and metabolic health reasons. From Ramadan observance to intermittent fasting trends, many individuals choose to abstain from food and fluids for extended periods despite potential risks. For clinicians, this creates an important challenge. Simply advising patients not to fast often …
Read More »GLP-1 Prescribing Without Baseline Data: Are We Skipping Critical Assessments?
A proper baseline assessment for GLP-1 therapy has become a critical yet sometimes overlooked step in modern diabetes care. In fast-moving clinical environments, especially with the rise of telehealth, providers may feel pressure to initiate GLP-1 therapy quickly. However, skipping essential baseline evaluations can lead to missed risks, poor outcomes, …
Read More »Reassessing Hypoglycemia Risk in the Era of Modern Therapies
Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …
Read More »GLP-1s and Gallbladder Disease: Risk Stratification and Monitoring in 2026
The expanding use of GLP-1 receptor agonists for type 2 diabetes and obesity has transformed metabolic care. However, growing awareness of the potential gallbladder risks associated with GLP-1 therapy has prompted clinicians to take a closer look at hepatobiliary safety. Rapid weight loss and altered bile composition during treatment may …
Read More »GLP-1s and Pancreatic Cancer: Reassessing Long-Term Safety Signals
Concerns about GLP-1 pancreatic cancer risk have circulated for more than a decade. When glucagon-like peptide-1 receptor agonists first entered the market, early post-marketing reports and small observational studies raised alarms about pancreatitis and possible malignancy. As a result, clinicians and patients questioned the long-term safety of agents such as …
Read More »How to Vet Diabetes Devices: A Clinic Checklist for Safe Tech Adoption
As diabetes technology evolves at lightning speed, clinics are under increasing pressure to evaluate a growing range of tools—from continuous glucose monitors (CGMs) and insulin pumps to smartphone apps and cloud platforms. But how can healthcare providers make safe, informed decisions about which tools to recommend? A clear, structured diabetes …
Read More »Dosing Error Due to Misinterpretation
When reviewing the medical record of a hospital patient before meeting with her for a diabetes consult, I noted that the doctor had ordered 46 units of Lantus to be given daily at bedtime....
Read More »Mail-Order Mix-Up
During a recent phone follow-up call to one of my patients, a co-worker and I avoided a "Diabetes Disaster." My patient told me that she had received her mail-order refill for "ASPART," but the bottle didn't look the same....
Read More »Best Plan for Patient May Not Be The Recommended Plan
Female, type 1 diabetes for 42 years, 58 years of age, lives with husband and dog. The patient has hypoglycemic unawareness. We regularly readjust her treatment plan and have recommended CGM for this patient on numerous occasions. Still, she refuses, stating her dog wakes her up if and when she has hypoglycemia. She called to let us know her dog passed away....
Read More »Diabetes and Tattoos: Case Study and Guidance
A 29-year-old woman with insulin-dependent diabetes noted a painful erosion at the site of the tattoo which she had gotten 7 days before. A culture isolated staphylococcus aureus confirming the clinical impression of staph. This diagnosis was not entirely unexpected, since patients with diabetes mellitus are predisposed to staphylococcal infection.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.